Join the conversation
by Robert Lederer, MD | April 15, 2011Might be good to include some comments on the use of Abiraterone which is in phase III clinical trials. Many lay people are hearing about it on the internet and most have been very positive reports. REPLY HERE
Comments from your colleagues...
On the new NCCN Guidelines for Prostate Cancer
by Robert Lederer, MD | April 15, 2011
Might be good to include some comments on the use of Abiraterone which is in phase III clinical trials. Many lay people are hearing about it on the internet and most have been very positive reports. REPLY HERE
by Gregg Dickerson, MD | April 15, 2011
Of greatly more interest to men with prostate cancer is inclusion of CyberKnife SBRT for prostate cancer in NCCN guidelines. Aetna, United, Cigna (with medical director approval), and Anthem (when denials are appealed) are paying for this modality based on the available data (5 year data). All MACs, (except for Trailblazer and Noridian) are covering this procedure. CyberKnife SBRT for prostate cancer costs less than half of what IMRT costs, and the 5 year data is demonstrating it to be superior with respect to toxicity and at least equal, if not superior, with respect to biochemical freedom from disease relapse. REPLY HERE
Elevating the Quality of Cancer Care via Cross-Department Collaboration
Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
